Pfizer Confirms EU Pegfilgrastim Launch Plans

Follows Formal European Commission Approval For Nyvepria Biosimilar

Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.

Red_Rocket
Pfizer has confirmed a launch window for its Nyvepria pegfilgrastim biosimilar • Source: Shutterstock

Pfizer has revealed that it plans to launch its Nyvepria (pegfilgrastim) biosimilar rival to Amgen’s Neulasta in Europe early next year. The confirmation of the launch plans follows the recent formal European Commission approval of Nyvepria in the wake of a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in September. (Also see "Pfizer Picks Up EU Pegfilgrastim Approval" - Generics Bulletin, 24 November, 2020.)

“Pfizer intends to make Nyvepria available to patients in several European countries starting in Q1 2021,” a Pfizer spokesperson told...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Archive

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Prescribed Medications for Attention Deficit Hyperactivity Disorder) - Clone - Clone

 
• By 

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

Testing-Rising

 
• By 

Testing-Rising xxxx

bhvyuguig

lnkbkb

test 1

test 1

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C11

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C10

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.